Breakthrough febrile neutropenia and associated complications among elderly cancer patients receiving myelosuppressive chemotherapy for solid tumors and lymphomas

Supportive Care in Cancer

Volumn 21, Issue 8, 2013, Pages 2137-2143

  Chan, Alexandre ^a,b   Lee, Chee Ping ^b   Chiang, Joen ^b   Ng, Raymond ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Breakthrough febrile neutropenia; Colony stimulating factors; Elderly; G CSF

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISOLONE; RITUXIMAB; TRASTUZUMAB; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; COHORT ANALYSIS; COMORBIDITY; FEBRILE NEUTROPENIA; FEMALE; HODGKIN DISEASE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUROENDOCRINE TUMOR; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; OBSERVATIONAL STUDY; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; SOLID TUMOR;

EID: 84984559177     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-013-1768-9     Document Type: Article

References (19)

1. National Comprehensive Cancer Network. Myeloid Growth Factors. www.nccn.org/professionals/physicians-gls/pdf/myeloidgrowth.pdf. Accessed 23 Feb 2013
2. Aapro MS, Cameron DA, Pettengell R et al (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42:2433-2453
3. Smith TJ, Khatcheressian J, Lyman GH et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187-3205
4. Aapro M, Schwenkglenks M, Lyman GH et al (2010) Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy. Crit Rev Oncol Hematol 74:203-210
5. Lyman GH, Kuderer NM, Crawford J et al (2011) Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 117:1917-1927
6. Aapro M, Crawford J, Kamioner D (2010) Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now? Support Care Cancer 18:529-541
7. Balducci L, Hardy CL, Lyman GH (2001) Hematopoietic growth factors in the older cancer patient. Curr Opin Hematol 8:170-187
8. Aapro MS, Bohlius J, Cameron DA et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8-32
9. Segal BH, Freifeld AG, Baden LR et al (2008) Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw 6:122-174
10. Jenkins P, Freeman S (2009) Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer. Ann Oncol 20:34-40
11. Chan A, Chen C, Chiang J et al (2012) Incidence of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy. Support Care Cancer 20:1525-1532
12. Chan A, Fu WH, Shih V et al (2011) Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy. Support Care Cancer 19:497-504
13. The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994
14. Coiffier B, Lepage E, Briere J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242
15. Coiffier B, Thieblemont C, Van Den Neste E et al (2010) Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 116:2040-2045
16. Salar A, Haioun C, Rossi FG et al (2012) The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice. Leuk Res 36:548-553
17. Rajan SS, Stearns SC, Lyman GH et al (2011) Effect of primary prophylactic G-CSF use on systemic therapy administration for elderly breast cancer patients. Breast Cancer Res Treat 130:255-266
18. Pettengell R, Bosly A, Szucs TD et al (2009) Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. Br J Haematol 144:677-685
19. Cullen M, Steven N, Billingham L et al (2005) Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 353:988-998